Wall Street brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to post sales of $12.32 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $10.40 million and the highest is $13.96 million. Theravance Biopharma posted sales of $4.52 million in the same quarter last year, which would indicate a positive year over year growth rate of 172.6%. The firm is expected to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $57.86 million for the current year, with estimates ranging from $55.00 million to $60.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $75.73 million, with estimates ranging from $56.30 million to $100.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The business had revenue of $12.84 million during the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative return on equity of 505.90% and a negative net margin of 513.41%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its stake in Theravance Biopharma by 4.6% in the 2nd quarter. Rhumbline Advisers now owns 39,781 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 1,757 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Theravance Biopharma by 7.2% in the 3rd quarter. Virtus ETF Advisers LLC now owns 32,226 shares of the biopharmaceutical company’s stock valued at $1,053,000 after purchasing an additional 2,171 shares in the last quarter. United Services Automobile Association purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $210,000. Xact Kapitalforvaltning AB purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $285,000. Finally, Man Group plc purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $292,000. 83.93% of the stock is owned by hedge funds and other institutional investors.
Shares of TBPH stock traded up $0.10 during trading hours on Friday, reaching $27.15. 108,300 shares of the company’s stock were exchanged, compared to its average volume of 165,137. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -4.98 and a beta of 1.89. Theravance Biopharma has a 1 year low of $21.27 and a 1 year high of $35.48. The company has a current ratio of 3.26, a quick ratio of 3.08 and a debt-to-equity ratio of 6.52.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
Recommended Story: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.